IMNM vs INBX: fair value comparison
Immunome, Inc. and Inhibrx Biosciences, Inc. · Updated 2026-10-19
IMNM has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. INBX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, IMNM currently ranks higher by quality score.
| IMNM | INBX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $16.47 | $89.83 |
| 12-month range | $15.24–$29.82 | $28.36–$141.84 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #242 of 301 Healthcare | #244 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Declining | Declining |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: IMNM fair value analysis · INBX fair value analysis